Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
PLoS Pathog ; 20(4): e1012166, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38635823

RESUMEN

Trypanosoma brucei are protozoan parasites that cause sleeping sickness in humans and nagana in cattle. Inside the mammalian host, a quorum sensing-like mechanism coordinates its differentiation from a slender replicative form into a quiescent stumpy form, limiting growth and activating metabolic pathways that are beneficial to the parasite in the insect host. The post-translational modification of proteins with the Small Ubiquitin-like MOdifier (SUMO) enables dynamic regulation of cellular metabolism. SUMO can be conjugated to its targets as a monomer but can also form oligomeric chains. Here, we have investigated the role of SUMO chains in T. brucei by abolishing the ability of SUMO to polymerize. We have found that parasites able to conjugate only SUMO monomers are primed for differentiation. This was demonstrated for monomorphic lines that are normally unable to produce stumpy forms in response to quorum sensing signaling in mice, and also for pleomorphic cell lines in which stumpy cells were observed at unusually low parasitemia levels. SUMO chain mutants showed a stumpy compatible transcriptional profile and better competence to differentiate into procyclics. Our study indicates that SUMO depolymerization may represent a coordinated signal triggered during stumpy activation program.


Asunto(s)
Trypanosoma brucei brucei , Animales , Trypanosoma brucei brucei/metabolismo , Ratones , Tripanosomiasis Africana/parasitología , Diferenciación Celular , Proteínas Modificadoras Pequeñas Relacionadas con Ubiquitina/metabolismo , Proteínas Protozoarias/metabolismo , Proteínas Protozoarias/genética , Procesamiento Proteico-Postraduccional , Percepción de Quorum/fisiología , Humanos , Sumoilación
2.
Sci Rep ; 8(1): 8743, 2018 Jun 04.
Artículo en Inglés | MEDLINE | ID: mdl-29867193

RESUMEN

A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.

3.
PLoS One ; 13(2): e0193528, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29474435

RESUMEN

SUMOylation is a post-translational modification conserved in eukaryotic organisms that involves the covalent attachment of the small ubiquitin-like protein SUMO to internal lysine residues in target proteins. This tag usually alters the interaction surface of the modified protein and can be translated into changes in its biological activity, stability or subcellular localization, among other possible outputs. SUMO can be attached as a single moiety or as SUMO polymers in case there are internal acceptor sites in SUMO itself. These chains have been shown to be important for proteasomal degradation as well as for the formation of subnuclear structures such as the synaptonemal complex in Saccharomyces cerevisiae or promyelocytic leukemia nuclear bodies in mammals. In this work, we have examined SUMO chain formation in the protozoan parasite Trypanosoma brucei. Using a recently developed bacterial strain engineered to produce SUMOylated proteins we confirmed the ability of TbSUMO to form polymers and determined the type of linkage using site-directed mutational analysis. By generating transgenic procyclic parasites unable to form chains we demonstrated that although not essential for normal growth, SUMO polymerization determines the localization of the modified proteins in the nucleus. In addition, FISH analysis of telomeres showed a differential positioning depending on the polySUMOylation abilities of the cells. Thus, our observations suggest that TbSUMO chains might play a role in establishing interaction platforms contributing to chromatin organization.


Asunto(s)
Núcleo Celular/metabolismo , Cromatina/metabolismo , Multimerización de Proteína , Proteínas Modificadoras Pequeñas Relacionadas con Ubiquitina/química , Proteínas Modificadoras Pequeñas Relacionadas con Ubiquitina/metabolismo , Trypanosoma brucei brucei/citología , Trypanosoma brucei brucei/metabolismo , Secuencias de Aminoácidos , Secuencia de Aminoácidos , Lisina/metabolismo , Modelos Moleculares , Mutación , Estructura Cuaternaria de Proteína , Proteínas Modificadoras Pequeñas Relacionadas con Ubiquitina/genética
4.
Sci Rep ; 7(1): 12073, 2017 09 21.
Artículo en Inglés | MEDLINE | ID: mdl-28935948

RESUMEN

American Trypanosomiasis or Chagas disease is a prevalent, neglected and serious debilitating illness caused by the kinetoplastid protozoan parasite Trypanosoma cruzi. The current chemotherapy is limited only to nifurtimox and benznidazole, two drugs that have poor efficacy in the chronic phase and are rather toxic. In this scenario, more efficacious and safer drugs, preferentially acting through a different mechanism of action and directed against novel targets, are particularly welcome. Cruzipain, the main papain-like cysteine peptidase of T. cruzi, is an important virulence factor and a chemotherapeutic target with excellent pre-clinical validation evidence. Here, we present the identification of new Cruzipain inhibitory scaffolds within the GlaxoSmithKline HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two collections grouping 404 non-cytotoxic compounds with high antiparasitic potency, drug-likeness, structural diversity and scientific novelty. We have adapted a continuous enzymatic assay to a medium-throughput format and carried out a primary screening of both collections, followed by construction and analysis of dose-response curves of the most promising hits. Using the identified compounds as a starting point a substructure directed search against CHEMBL Database revealed plausible common scaffolds while docking experiments predicted binding poses and specific interactions between Cruzipain and the novel inhibitors.


Asunto(s)
Antiprotozoarios/farmacología , Ensayos Analíticos de Alto Rendimiento/métodos , Kinetoplastida/efectos de los fármacos , Proteínas Protozoarias/antagonistas & inhibidores , Antiprotozoarios/química , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/parasitología , Cisteína Endopeptidasas/química , Cisteína Endopeptidasas/metabolismo , Interacciones Huésped-Parásitos/efectos de los fármacos , Humanos , Kinetoplastida/enzimología , Kinetoplastida/fisiología , Simulación del Acoplamiento Molecular , Estructura Molecular , Nifurtimox/química , Nifurtimox/farmacología , Nitroimidazoles/química , Nitroimidazoles/farmacología , Dominios Proteicos , Proteínas Protozoarias/química , Proteínas Protozoarias/metabolismo , Trypanosoma cruzi/efectos de los fármacos , Trypanosoma cruzi/enzimología , Trypanosoma cruzi/fisiología
5.
PLoS One ; 10(8): e0134950, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26258470

RESUMEN

Post-translational modification with the Small Ubiquitin-like Modifier (SUMO) is conserved in eukaryotic organisms and plays important regulatory roles in proteins affecting diverse cellular processes. In Trypanosoma brucei, member of one of the earliest branches in eukaryotic evolution, SUMO is essential for normal cell cycle progression and is likely to be involved in the epigenetic control of genes crucial for parasite survival, such as those encoding the variant surface glycoproteins. Molecular pathways modulated by SUMO have started to be discovered by proteomic studies; however, characterization of functional consequences is limited to a reduced number of targets. Here we present a bacterial strain engineered to produce SUMOylated proteins, by transferring SUMO from T. brucei together with the enzymes essential for its activation and conjugation. Due to the lack of background in E. coli, this system is useful to express and identify SUMOylated proteins directly in cell lysates by immunoblotting, and SUMOylated targets can be eventually purified for biochemical or structural studies. We applied this strategy to describe the ability of TbSUMO to form chains in vitro and to detect SUMOylation of a model substrate, PCNA both from Saccharomyces cerevisiae and from T. brucei. To further validate targets, we applied an in vitro deconjugation assay using the T. brucei SUMO-specific protease capable to revert the pattern of modification. This system represents a valuable tool for target validation, mutant generation and functional studies of SUMOylated proteins in trypanosomatids.


Asunto(s)
Proteínas Recombinantes/biosíntesis , Proteínas Modificadoras Pequeñas Relacionadas con Ubiquitina/metabolismo , Sumoilación , Trypanosoma brucei brucei/enzimología , Alelos , Ciclo Celular , Escherichia coli/metabolismo , Genómica , Immunoblotting , Lisina/química , Mutación , Sistemas de Lectura Abierta , Péptido Hidrolasas/metabolismo , Plásmidos/metabolismo , Reacción en Cadena de la Polimerasa , Proteómica , Saccharomyces cerevisiae/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA